EICHORPublic-registry site landscape for NCT06436183, “A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis”, a Atopic Dermatitis study sponsored by Apollo Therapeutics Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06436183 (registry record) |
| Study title | A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis |
| Official title | A Phase 2a, Multicenter, Randomized, Double-blind, 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis |
| Sponsor | Apollo Therapeutics Ltd |
| Condition(s) | Atopic Dermatitis; Atopic; Dermatitis; Dermatologic Disease |
| Phase | PHASE2 |
| Listed sites | 35 |
| Intervention(s) | Camoteskimab, Placebo |
| Site countries | United States, Canada |
Patient-friendly overview of this study: eichor.com/study/NCT06436183.
Eichor generates a preliminary site-risk snapshot for NCT06436183 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
